Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20406585 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL23902600 | 0.86 | CHRM2 (0.39) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL21470687 | 0.86 | CHRM2 (0.39) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL15018313 | 0.86 | CHRM2 (0.42) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8445549 | 0.86 | CHRM2 (0.39) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8269698 | 0.84 | CHRM2 (0.44) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL13956844 | 0.84 | CHRM2 (0.44) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL625885 | 0.84 | CHRM2 (0.44) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL22096750 | 0.83 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL19420020 | 0.83 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | CHRM2 2449/4885CHRM1 1846/4885CHRM3 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.